Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Interferon | Research

The prognostic and clinical significance of IFI44L aberrant downregulation in patients with oral squamous cell carcinoma

Authors: Deming Ou, Ying Wu

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

It is a basic task in high-throughput gene expression profiling studies to identify differentially expressed genes (DEGs) between two phenotypes. RankComp, an algorithm, could analyze the highly stable within-sample relative expression orderings (REOs) of gene pairs in a particular type of human normal tissue that are widely reversed in the cancer condition, thereby detecting DEGs for individual disease samples measured by a particular platform.

Methods

In the present study, Gene Expression Omnibus (GEO) Series (GSE) GSE75540, GSE138206 were downloaded from GEO, by analyzing DEGs in oral squamous cell carcinoma based on online datasets using the RankComp algorithm, using the Kaplan-Meier survival analysis and Cox regression analysis to survival analysis, Gene Set Enrichment Analysis (GSEA) to explore the potential molecular mechanisms underlying.

Results

We identified 6 reverse gene pairs with stable REOs. All the 12 genes in these 6 reverse gene pairs have been reported to be associated with cancers. Notably, lower Interferon Induced Protein 44 Like (IFI44L) expression was associated with poorer overall survival (OS) and Disease-free survival (DFS) in oral squamous cell carcinoma patients, and IFI44L expression showed satisfactory predictive efficiency by receiver operating characteristic (ROC) curve. Moreover, low IFI44L expression was identified as risk factors for oral squamous cell carcinoma patients’ OS. IFI44L downregulation would lead to the activation of the FRS-mediated FGFR1, FGFR3, and downstream signaling pathways, and might play a role in the PI3K-FGFR cascades.

Conclusions

Collectively, we identified 6 reverse gene pairs with stable REOs in oral squamous cell carcinoma, which might serve as gene signatures playing a role in the diagnosis in oral squamous cell carcinoma. Moreover, high expression of IFI44L, one of the DEGs in the 6 reverse gene pairs, might be associated with favorable prognosis in oral squamous cell carcinoma patients and serve as a tumor suppressor by acting on the FRS-mediated FGFR signaling.
Appendix
Available only for authorised users
Literature
1.
Lala M, et al. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): a systematic literature review. Oral Oncol. 2018;84:108–20.PubMedCrossRef
2.
Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma--an update. CA Cancer J Clin. 2015;65(5):401–21.PubMedCrossRef
3.
Sasahira T, Kirita T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma. Int J Mol Sci. 2018:19(8).
4.
Tota JE, et al. Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. Oral Oncol. 2017;67:146–52.PubMedCrossRef
5.
Moore SR, et al. The epidemiology of tongue cancer: a review of global incidence. Oral Dis. 2000;6(2):75–84.PubMedCrossRef
6.
Hussein AA, et al. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: a systematic review. Eur J Cancer. 2017;82:115–27.PubMedCrossRef
7.
Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet. 2002;360(9340):1131–5.PubMedCrossRef
8.
Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer. 2005;103(9):1843–9.PubMedCrossRef
9.
Almangush A, et al. Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis. Br J Cancer. 2017;117(6):856–66.PubMedPubMedCentralCrossRef
10.
Hussein AA, et al. A review of the most promising biomarkers for early diagnosis and prognosis prediction of tongue squamous cell carcinoma. Br J Cancer. 2018;119(6):724–36.PubMedPubMedCentralCrossRef
11.
Barrett T, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991–5.PubMed
12.
Parkinson H, et al. ArrayExpress--a public database of microarray experiments and gene expression profiles. Nucleic Acids Res. 2007;35(Database issue):D747–50.PubMedCrossRef
13.
Leek JT, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11(10):733–9.PubMedCrossRef
14.
Nygaard V, Rodland EA, Hovig E. Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses. Biostatistics. 2016;17(1):29–39.PubMedCrossRef
15.
16.
Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118–27.PubMedCrossRef
17.
Rhodes DR, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002;62(15):4427–33.PubMed
18.
Hu P, Greenwood CM, Beyene J. Integrative analysis of multiple gene expression profiles with quality-adjusted effect size models. BMC Bioinformatics. 2005;6:128.PubMedPubMedCentralCrossRef
19.
Choi JK, et al. Combining multiple microarray studies and modeling interstudy variation. Bioinformatics. 2003;19(Suppl 1):i84–90.PubMedCrossRef
20.
Hong F, et al. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics. 2006;22(22):2825–7.PubMedCrossRef
21.
Zintzaras E, Ioannidis JP. Meta-analysis for ranked discovery datasets: theoretical framework and empirical demonstration for microarrays. Comput Biol Chem. 2008;32(1):38–46.PubMedCrossRef
22.
23.
24.
25.
26.
27.
Li B, et al. Bayesian inference with historical data-based informative priors improves detection of differentially expressed genes. Bioinformatics. 2016;32(5):682–9.PubMedCrossRef
28.
Wang D, et al. Extensive up-regulation of gene expression in cancer: the normalised use of microarray data. Mol BioSyst. 2012;8(3):818–27.PubMedCrossRef
29.
30.
Lazar C, et al. Batch effect removal methods for microarray gene expression data integration: a survey. Brief Bioinform. 2013;14(4):469–90.PubMedCrossRef
31.
Guan Q, et al. Differential expression analysis for individual cancer samples based on robust within-sample relative gene expression orderings across multiple profiling platforms. Oncotarget. 2016;7(42):68909–20.PubMedPubMedCentralCrossRef
32.
Cai H, et al. A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients. Breast Cancer Res Treat. 2018;170(2):271–7.PubMedCrossRef
33.
Hu G, et al. Identification of potential key genes associated with osteosarcoma based on integrated bioinformatics analyses. J Cell Biochem. 2019;120(8):13554–61.PubMedCrossRef
34.
Geman, D., et al. Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol, 2004. 3: p. Article19.
35.
Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.PubMedPubMedCentralCrossRef
36.
Mootha VK, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.PubMedCrossRef
37.
Zhang FP, et al. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. World J Gastroenterol. 2020;26(2):134–53.PubMedPubMedCentralCrossRef
38.
Laszlo GS, et al. Multimerin-1 (MMRN1) as novel adverse marker in pediatric acute myeloid leukemia: a report from the Children's oncology group. Clin Cancer Res. 2015;21(14):3187–95.PubMedPubMedCentralCrossRef
39.
Huang, H., Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel), 2018. 18(10).
40.
41.
Wang Y, et al. Upregulated LAMB3 increases proliferation and metastasis in thyroid cancer. Onco Targets Ther. 2018;11:37–46.PubMedCrossRef
42.
Laroussi N, et al. Identification of a novel mutation of LAMB3 gene in a Lybian patient with hereditary epidermolysis bullosa by whole exome sequencing. Ann Dermatol. 2017;29(2):243–6.PubMedPubMedCentralCrossRef
43.
Hou J, Wang L, Wu D. The root of Actinidia chinensis inhibits hepatocellular carcinomas cells through LAMB3. Cell Biol Toxicol. 2018;34(4):321–32.PubMedCrossRef
44.
Wang Q, et al. Tamoxifen enhances stemness and promotes metastasis of ERalpha36(+) breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 2018;28(3):336–58.PubMedPubMedCentralCrossRef
45.
Ciccone V, et al. Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1alpha/VEGF signalling in MCF-7 breast cancer cells. J Exp Clin Cancer Res. 2018;37(1):311.PubMedPubMedCentralCrossRef
46.
Xu JS, et al. Combining bioinformatics techniques to explore the molecular mechanisms involved in pancreatic cancer metastasis and prognosis. J Cell Mol Med. 2020.
47.
Masaoka H, et al. Aldehyde dehydrogenase 2 (ALDH2) and alcohol dehydrogenase 1B (ADH1B) polymorphisms exacerbate bladder cancer risk associated with alcohol drinking: gene-environment interaction. Carcinogenesis. 2016;37(6):583–8.PubMedCrossRef
48.
Ishioka K, et al. Association between ALDH2 and ADH1B polymorphisms, alcohol drinking and gastric cancer: a replication and mediation analysis. Gastric Cancer. 2018;21(6):936–45.PubMedCrossRef
49.
Lilla C, et al. Alcohol dehydrogenase 1B (ADH1B) genotype, alcohol consumption and breast cancer risk by age 50 years in a German case-control study. Br J Cancer. 2005;92(11):2039–41.PubMedPubMedCentralCrossRef
50.
Guo J, et al. Clinicopathological significance of orphan nuclear receptor Nurr1 expression in gastric cancer. Clin Transl Oncol. 2015;17(10):788–94.PubMedCrossRef
51.
Han Y, et al. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy. Eur J Cancer. 2013;49(16):3420–30.PubMedCrossRef
52.
Wang J, et al. Orphan nuclear receptor nurr1 as a potential novel marker for progression in human prostate cancer. Asian Pac J Cancer Prev. 2013;14(3):2023–8.PubMedCrossRef
53.
Inamoto T, et al. 1,1-Bis(3′-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther. 2008;7(12):3825–33.PubMedPubMedCentralCrossRef
54.
Liu J, et al. HOXB2 is a putative tumour promotor in human bladder Cancer. Anticancer Res. 2019;39(12):6915–21.PubMedCrossRef
55.
Li, H., et al. miR-4324 functions as a tumor suppressor in colorectal cancer by targeting HOXB2. J Int Med Res, 2020. 48(3): p. 300060519883731.
56.
Segara D, et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res. 2005;11(9):3587–96.PubMedCrossRef
57.
Qi K, et al. Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway. Anti-Cancer Drugs. 2016;27(10):970–8.PubMedCrossRef
58.
59.
60.
Huang WC, et al. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway. BMC Cancer. 2018;18(1):609.PubMedPubMedCentralCrossRef
61.
Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36.PubMedCrossRef
62.
Wang H, et al. Individual-level analysis of differential expression of genes and pathways for personalized medicine. Bioinformatics. 2015;31(1):62–8.PubMedCrossRef
63.
64.
Li H, et al. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Oncotarget. 2017;8(32):52571–83.PubMedPubMedCentralCrossRef
65.
Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29.PubMedCrossRef
66.
Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18(7):1855–62.PubMedCrossRef
67.
Dienstmann R, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25(3):552–63.PubMedCrossRef
68.
Dieci MV, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3(3):264–79.PubMedCrossRef
69.
70.
71.
72.
Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17(5):318–32.PubMedCrossRef
73.
Stafford F, et al. Organisation and provision of head and neck cancer surgical services in the United Kingdom: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S5–8.PubMedPubMedCentralCrossRef
Metadata
Title
The prognostic and clinical significance of IFI44L aberrant downregulation in patients with oral squamous cell carcinoma
Authors
Deming Ou
Ying Wu
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Interferon
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-09058-y

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue

Research article

Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study

Research

Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews

Research article

Prognostic nomogram for predicting long-term cancer-specific survival in patients with lung carcinoid tumors

Research

Can addition of frozen section analysis to preoperative endometrial biopsy and MRI improve identification of high-risk endometrial cancer patients?

Study protocol

Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial

Research article

Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits